Assurance de qualité pour le cancer rectal – phase 2 ...

More documents

Recommendations

Info

138 PROCARE – phase 2 KCE reports 81PROPORTION OF (Y)PSTAGE II-III PATIENTS WITH R0 RESECTIONTHAT STARTED ADJUVANT CHEMOTHERAPY WITHIN 12 WEEKSAFTER SURGICAL RESECTIONMeasurement in prospective PROCARE database (Figure 48)Patients with (y)pStage II-III RC are selected through variable ‘PT_V151’. Those patientsundergoing R0 resection are selected using variable ‘SG_V216’ (subcode 1). Patientsreceiving adjuvant chemotherapy are selected with variables ‘CH_V104’ (subcode 1)and ‘CH_V106’ (subcode not 2). The dates of surgery and chemotherapy are registeredthrough variables ‘SG_V106’ and ‘CH_V115’ respectively, allowing the calculation of thetime interval between the two treatments.Measurement in coupled administrative databaseSelection of (y)pStage II-III patients can be done easily using the BCR database. Abovethis, accurate information is available on the use of adjuvant chemotherapy (Table 72)and the surgery date (Table 64 and 66). However, no administrative code exists for R0resection. Therefore, this QI is not measurable for the administrative cohort.Figure 48. Algorithm for QI 1243 (prospective database).All patientsN=1071R1 resectionR2 resectionUncertainN=64Adjuvant chemo(radio)therapyN=54Stage?pyp-Stage II-IIIN=569Surgery?Type ofresection?Type of resectionMISSINGN=13R0 resectionN=492Chemotherapywithin12 weeksafter surgery?Chemotherapy within 12weeks after surgeryN=3391,67%Chemotherapy after morethan 12 weeks after surgeryN=3SurgeryN=569Treatmentafter surgery?Date chemotherapy and/orsurgery not knownN=18pyp-Stage 0-I-IVN=321No surgeryN=0Adjuvant radiotherapy onlyN=0No adjuvant treatmentpyp-stageUnknownN=181N=178Adjuvant treatmentchemotherapy=MISSINGN=260
KCE Reports 81 PROCARE – phase 2 139PROPORTION OF (Y)PSTAGE II-III PATIENTS WITH R0 RESECTIONTREATED WITH ADJUVANT CHEMO(RADIO)THERAPY, THATRECEIVED 5-FU BASED CHEMOTHERAPYMeasurement in prospective PROCARE database (Figure 49)Patients with (y)pStage II-III RC are selected through variable ‘PT_V151’. Those patientsundergoing R0 resection are selected using variable ‘SG_V216’ (subcode 1). Patientsreceiving adjuvant chemotherapy are selected with variables ‘CH_V104’ (subcode 1)and ‘CH_V106’ (subcode not 2). The use of a 5-FU based regimen is registered throughvariable ‘CH_V110’.Measurement in coupled administrative databaseSelection of (y)pStage II-III patients can be done easily using the BCR database. Abovethis, accurate information is available on the use of adjuvant chemo(radio)therapy (Table70, 71 and 72). However, no administrative code exists for R0 resection. Therefore,this QI is not measurable for the administrative cohort.Figure 49. Algorithm for QI 1244 (prospective database).All patientsN=1071R1 resectionR2 resectionUncertainN=64Adjuvant chemo(radio)therapyN=54Stage?pyp-Stage II-IIIN=569Type ofresection?Type of resectionMISSINGN=13R0 resectionN=4925-FU basedchemotherapy?Adjuvant chemotherapy with5-FU regimenN=3394,29%Adjuvant chemotherapy withother than 5-FU-regimenN=2Surgery?SurgeryN=569Treatmentaftersurgery?MISSING:regimen adjuvantchemotherapyN=19No surgeryN=0pyp-Stage 0-I-IVN=321pyp-Stage UnknownN=181Adjuvant radiotherapy onlyN=0No adjuvant treatmentN=178Adjuvant treatmentchemotherapy=MISSINGN=260
Page 1 and 2:
Assurance de qualitépour le cancer
Page 3 and 4:
Assurance de qualité pour lecancer
Page 5 and 6:
KCE Reports 81B Cancer rectal - pha
Page 7:
KCE Reports 81B Cancer rectal - pha
Page 10 and 11:
vi Cancer rectal - phase 2 KCE Repo
Page 12 and 13:
2 PROCARE - phase 2 KCE reports 81A
Page 14 and 15:
4 PROCARE - phase 2 KCE reports 811
Page 16 and 17:
6 PROCARE - phase 2 KCE reports 81F
Page 19 and 20:
KCE Reports 81 PROCARE - phase 2 92
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
KCE Reports 81 PROCARE - Phase 2 77
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98: KCE Reports 81 PROCARE - phase 2 87
Page 147: KCE Reports 81 PROCARE - phase 2 13
Page 169: KCE Reports 81 PROCARE - phase 2 15
Page 172 and 173: Dépôt légal : D/2008/10.273/39
Page 174 and 175: 35. Etude relative aux coûts poten
show all

Assurance de qualité pour le cancer rectal – phase 2 ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?